Access Pharmaceuticals, Inc. has entered into an agreement with a major pharmaceutical company to use its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics. Access will provide CobOral and CobaCyte siRNA formulations for evaluation of gene knockdown following oral and intravenous administration. According to Access, any successful formulation developed will be jointly owned and subject to a subsequent full licensing agreement. Terms of the agreement were not disclose...